GLP-1 analog liraglutide protects against cardiac steatosis, oxidative stress and apoptosis in streptozotocin-induced diabetic rats

Atherosclerosis

Volumn 240, Issue 1, 2015, Pages 250-259

  Inoue, Tomoaki ^a   Inoguchi, Toyoshi ^a,b   Sonoda, Noriyuki ^a,b   Hendarto, Hari ^a   Makimura, Hiroaki ^a   Sasaki, Shuji ^a   Yokomizo, Hisashi ^a   Fujimura, Yoshinori ^b   Miura, Daisuke ^b   Takayanagi, Ryoichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Cardiac steatosis; Diabetic cardiomyopathy; Glucagon like peptide 1; Oxidative stress; Protein kinase C

Indexed keywords

ACYLGLYCEROL PALMITOYLTRANSFERASE; CASPASE 3; CD36 ANTIGEN; DIACYLGLYCEROL; GLUCOSE; GLYCEROL 3 PHOSPHATE ACYLTRANSFERASE; INSULIN; LIRAGLUTIDE; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE C; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SIRTUIN 1; SUPEROXIDE; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INCRETIN; SIRT1 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CARDIAC STEATOSIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FATTY ACID OXIDATION; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HEART PROTECTION; INSULIN BLOOD LEVEL; LIPID METABOLISM; LIPID STORAGE; LIPID TRANSPORT; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; STEATOSIS; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; SYNTHESIS; TREATMENT DURATION; ANIMAL; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; DRUG EFFECTS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETICS; HEART MUSCLE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; WISTAR RAT;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; APOPTOSIS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; DIGLYCERIDES; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HYPOGLYCEMIC AGENTS; INCRETINS; LIPID METABOLISM; LIRAGLUTIDE; MALE; MYOCARDIUM; NADPH OXIDASE; OXIDATIVE STRESS; PHOSPHORYLATION; PROTEIN KINASE C; RATS, WISTAR; SIGNAL TRANSDUCTION; SIRTUIN 1; TRIGLYCERIDES;

EID: 84925355917     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.03.026     Document Type: Article

References (50)

1. Aneja A., Tang W.H., Bansilal S., et al. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am. J. Med. 2008, 121:748-757.
2. Rijzewijk L.J., van der Meer R.W., Smit J.W., et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J.Am. Coll. Cardiol. 2008, 52:1793-1799.
3. McGavock J.M., Lingvay I., Zib I., et al. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation 2007, 116:1170-1175.
4. Inoguchi T., Battan R., Handler E., et al. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:11059-11063.
5. Inoguchi T., Li P., Umeda F., et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000, 49:1939-1945.
6. Inoue T., Kobayashi K., Inoguchi T., et al. Downregulation of adipose triglyceride lipase in the heart aggravates diabetic cardiomyopathy in db/db mice. Biochem. Biophys. Res. Commun. 2013, 438(1):224-229.
7. Dirkx E., Schwenk R.W., Glatz J.F., et al. High fat diet induced diabetic cardiomyopathy. Prostagl. Leukot. Essent. Fat. Acids 2011, 85:219-225.
8. Koya D., King G.L. Protein kinase C activation and the development of diabetic complications. Diabetes 1998, 47:859-866.
9. Watanabe K., Thandavarayan R.A., Harima M., et al. Role of differential signaling pathways and oxidative stress in diabetic cardiomyopathy. Curr. Cardiol. Rev. 2010, 6:280-290.
10. Drucker D.J. The biology of incretin hormones. Cell Metab. 2006, 3:153-165.
11. Irwin D.M. Molecular evolution of proglucagon. Regul. Pept. 2001, 98:1-12.
12. Thorens B., Porret A., Buhler L., et al. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 1993, 42:1678-1682.
13. Bullock B.P., Heller R.S., Habener J.F. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996, 137:2968-2978.
14. Ussher J.R., Drucker D.J. Cardiovascular biology of the incretin system. Endocr. Rev. 2012, 33:187-215.
15. Noyan-Ashraf M.H., Momen M.A., Ban K., et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009, 58:975-983.
16. Bose A.K., Mocanu M.M., Carr R.D., et al. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005, 54:146-151.
17. Arakawa M., Mita T., Azuma K., et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010, 59:1030-1037.
18. Khan M.A., Deaton C., Rutter M.K., et al. Incretins as a novel therapeutic strategy in patients with diabetes and heart failure. Heart Fail Rev. 2012, 18(2):141-148.
19. Rolin B., Larsen M.O., Gotfredsen C.F., et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am. J. Physiol. Endocrinol. Metab. 2002, 283:E745-E752.
20. Sturis J., Gotfredsen C.F., Romer J., et al. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br. J. Pharmacol. 2003, 140:123-132.
21. Folch J., Lees M., Sloane Stanley G.H. Asimple method for the isolation and purification of total lipides from animal tissues. J.Biol. Chem. 1957, 226:497-509.
22. Inoue T., Kobayashi K., Inoguchi T., et al. Reduced expression of adipose triglyceride lipase enhances tumor necrosis factor {alpha}-induced intercellular adhesion molecule-1 expression in human aortic endothelial cells via protein kinase c-dependent activation of nuclear factor-{kappa}B. J.Biol. Chem. 2011, 286:32045-32053.
23. Etoh T., Inoguchi T., Kakimoto M., et al. Increased expression of NAD(P)H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibility by interventive insulin treatment. Diabetologia 2003, 46:1428-1437.
24. Johar S., Cave A.C., Narayanapanicker A., et al. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J. 2006, 20:1546-1548.
25. Febbraio M., Silverstein R.L. CD36: implications in cardiovascular disease. Int. J. Biochem. Cell Biol. 2007, 39:2012-2030.
26. Munday M.R. Regulation of mammalian acetyl-CoA carboxylase. Biochem. Soc. Trans. 2002, 30:1059-1064.
27. Canto C., Auwerx J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr. Opin. Lipidol. 2009, 20:98-105.
28. Chaudhary N., Pfluger P.T. Metabolic benefits from Sirt1 and Sirt1 activators. Curr. Opin. Clin. Nutr. Metab. Care 2009, 12:431-437.
29. Baynes J.W. Role of oxidative stress in development of complications in diabetes. Diabetes 1991, 40:405-412.
30. Oberley L.W. Free radicals and diabetes. Free Radic. Biol. Med. 1988, 5:113-124.
31. Ha H., Kim C., Son Y., et al. DNA damage in the kidneys of diabetic rats exhibiting microalbuminuria. Free Radic. Biol. Med. 1994, 16:271-274.
32. Kakimoto M., Inoguchi T., Sonta T., et al. Accumulation of 8-hydroxy-2'-deoxyguanosine and mitochondrial DNA deletion in kidney of diabetic rats. Diabetes 2002, 51:1588-1595.
33. Wolff S.P., Jiang Z.Y., Hunt J.V. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic. Biol. Med. 1991, 10:339-352.
34. Quagliaro L., Piconi L., Assaloni R., et al. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 2003, 52:2795-2804.
35. Frustaci A., Kajstura J., Chimenti C., et al. Myocardial cell death in human diabetes. Circ. Res. 2000, 87:1123-1132.
36. Cai L., Li W., Wang G., et al. Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes 2002, 51:1938-1948.
37. Taha M., Lopaschuk G.D. Alterations in energy metabolism in cardiomyopathies. Ann. Med. 2007, 39:594-607.
38. Carley A.N., Kleinfeld A.M. Fatty acid (FFA) transport in cardiomyocytes revealed by imaging unbound FFA is mediated by an FFA pump modulated by the CD36 protein. J.Biol. Chem. 2011, 286:4589-4597.
39. Picard F., Kurtev M., Chung N., et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 2004, 429:771-776.
40. Canto C., Gerhart-Hines Z., Feige J.N., et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 2009, 458:1056-1060.
41. Batchuluun B., Inoguchi T., Sonoda N., et al. Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells. Atherosclerosis 2014, 232:156-164.
42. Balteau M., Van Steenbergen A., Timmermans A.D., et al. AMPK activation by glucagon-like peptide-1 prevents NADPH oxidase activation induced by hyperglycemia in adult cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 2014, 307:H1120-H1133.
43. Coleman R.A., Lee D.P. Enzymes of triacylglycerol synthesis and their regulation. Prog. Lipid Res. 2004, 43:134-176.
44. Horton J.D., Goldstein J.L., Brown M.S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J.Clin. Invest. 2002, 109:1125-1131.
45. Ponugoti B., Kim D.H., Xiao Z., et al. SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism. J.Biol. Chem. 2010, 285:33959-33970.
46. Ha J., Daniel S., Broyles S.S., et al. Critical phosphorylation sites for acetyl-CoA carboxylase activity. J.Biol. Chem. 1994, 269:22162-22168.
47. Kim M., Platt M.J., Shibasaki T., et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat. Med. 2013, 19:567-575.
48. Noyan-Ashraf M.H., Shikatani E.A., Schuiki I., et al. Aglucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation 2013, 127:74-85.
49. Nogueiras R., Perez-Tilve D., Veyrat-Durebex C., et al. Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity. J.Neurosci. 2009, 29:5916-5925.
50. Xu M., Zhao Y.T., Song Y., et al. alpha1-adrenergic receptors activate AMP-activated protein kinase in rat hearts. Sheng Li Xue Bao 2007, 59:175-182.